CMS RAPID Medicare Device Coverage Pathway: What Beneficiaries Should Know

On August 11, 2026, the Centers for Medicare & Medicaid Services published a notice describing the Regulatory Alignment for Predictable and Immediate Device coverage pathway, known as RAPID. The pathway is intended to shorten the time between Food and Drug Administration market authorization and a national Medicare coverage decision for a narrow group of qualifying medical devices.

This is a procedural notice with a public comment period, not an announcement that Medicare now covers every Breakthrough Device. CMS says it will review comments and respond in a subsequent final notice. Comments on file code CMS-3487-NC are due October 13, 2026.

FDA decides whether a device may be marketed based on the standards that apply to that device. Medicare makes a separate coverage decision, generally asking whether an item or service falls within a Medicare benefit category and is reasonable and necessary for diagnosing or treating an illness or injury.

Under the proposed RAPID process, CMS would join FDA and eligible manufacturers earlier, while a device is still being developed. The agencies would work to align evidence expectations so a clinical study can address outcomes relevant to FDA review and to Medicare beneficiaries before the manufacturer requests national Medicare coverage.

The notice limits RAPID to certain presumptive Class II FDA-designated Breakthrough Devices participating in FDA’s Total Product Life Cycle Advisory Program and certain Class III FDA-designated Breakthrough Devices. A device generally must be early enough in development for CMS and FDA to provide input before an investigational study begins.

The planned study must enroll Medicare beneficiaries and evaluate appropriate clinical outcomes. The device also must meet other requirements: for example, it cannot already be controlled by an existing national coverage determination, excluded from coverage by law or regulation, or clearly outside a Medicare benefit category based on available information. In vitro diagnostic products, including diagnostic laboratory tests, would not be accepted into RAPID.

The FDA Breakthrough Devices Program and FDA market authorization do not, by themselves, determine whether Medicare will pay for a device. RAPID would coordinate the two agencies’ work, but CMS would still use the national coverage determination process and evaluate whether the evidence supports Medicare coverage.

If a qualifying device completes RAPID and demonstrates improved health outcomes, CMS says it would aim to post a proposed national coverage determination on the same day as FDA market authorization. The public would then have 30 days to comment on that proposed coverage decision before CMS issues a final decision.

CMS says its goal is to release a final national coverage determination about 60 days after FDA market authorization for qualifying Class II devices and about 90 days after authorization for qualifying Class III devices. That could reduce a delay that otherwise may occur while Medicare separately reviews a newly authorized technology.

Those timeframes do not mean a beneficiary can obtain any newly authorized device after 60 or 90 days. A particular device must enter and complete RAPID, meet the pathway requirements, produce sufficient evidence, receive FDA authorization, and receive a favorable final Medicare coverage decision. The final decision may also set specific conditions for coverage.

CMS may use coverage with evidence development when a device appears promising but important evidence gaps remain. Under that approach, Medicare coverage can depend on receiving the device in an approved clinical study or another structured evidence-development setting described in the national coverage determination.

Coverage with evidence development is not unrestricted coverage. The final policy may define which patients, providers, facilities, studies, or follow-up requirements qualify. CMS says these evidence-development decisions should be time-limited rather than remain in place indefinitely.

A favorable national coverage determination establishes Medicare policy across the country, but payment for an individual claim can still depend on the final decision’s eligibility criteria, medical necessity, documentation, the setting where the device is furnished, and whether the provider or supplier meets Medicare requirements.

Costs would also depend on how the device and related services are covered. A national coverage decision does not necessarily make care free. Deductibles, copays, or coinsurance may apply, and Medicare Advantage plans may use plan rules such as networks or prior authorization while providing at least the Medicare-covered benefit.

If a clinician recommends a new device, ask for its exact name and model, the FDA authorization status, and the Medicare coverage policy that applies. Confirm whether there is a final national coverage determination, a local coverage policy, or coverage with evidence development—and whether you meet every stated requirement.

Also ask the provider and your Medicare Advantage plan, if applicable, whether authorization is required, which facility and clinician must furnish the service, what related procedures and follow-up care are included, and what you may owe. A label such as “Breakthrough Device” or “RAPID-eligible” is not a coverage confirmation for your individual care.

RAPID is intended to improve the coverage-review process for future qualifying technologies. It does not identify one device as safer, more effective, or appropriate for a particular patient, and it should not replace a discussion with your treating clinician about benefits, risks, alternatives, and available evidence.

Beneficiaries and other members of the public may submit comments through the federal docket by October 13, 2026. For a personal coverage question, use Medicare’s coverage resources, review any written decision from Original Medicare or your plan, or call 1-800-MEDICARE. Medicare beneficiaries have the right to receive a coverage decision and appeal certain decisions with which they disagree.

CMS: “Regulatory Alignment for Predictable and Immediate Device Coverage Pathway (CMS-3487-NC) Procedural Notice Inviting Comment,” and “Medicare Coverage Determination Process.” Federal Register: “Medicare Program; Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway,” published August 11, 2026. Medicare.gov: “Your Rights.” These sources explain the proposed pathway, eligibility and timing goals, national coverage decisions, public comments, individual coverage decisions, and appeal rights.